Intra-Cellular Therapies ITCI reported its Q3 earnings results on Tuesday, November 9, 2021 at 08:00 AM.
Here's what investors need to know about the announcement.
Earnings
Intra-Cellular Therapies their estimated earnings by 3.26%, reporting an EPS of $-0.95 versus an estimate of $-0.92, which did not surprise analysts.
Revenue was up $14,838,000 from the same period last year.
Past Earnings Performance
Last quarter the company missed on EPS by $0.05, which was followed by a 8.8% drop in the share price the next day.
Here's a look at Intra-Cellular Therapies's past performance:
Quarter | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 |
---|---|---|---|---|
EPS Estimate | -0.80 | -0.80 | -0.85 | -1 |
EPS Actual | -0.85 | -0.65 | -0.76 | -0.79 |
Revenue Estimate | 19.44M | 16.50M | 11.84M | 5.86M |
Revenue Actual | 20.05M | 15.88M | 12.45M | 7.37M |
To track all upcoming earnings announcements, click to use Benzinga Earnings Calendar.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.